Positive results from follow-up of 30 patients in a Swedish multi-centre clinical trial of the Episealer® Knee implant
Episurf Medical (Nasdaq: EPIS B) today announces that results from a clinical study with follow-up of the 30 first patients from nine Swedish clinics show good implant safety and significantly improved patient-reported outcome scores. Follow-ups of the patients are now completed, and the principle investigator will compile the results for submission to a scientific journal. In total, 30 patients are included in the study and the average follow-up time is 55 months (24 – 86 months). The Episealer® Knee implant is intended for treatment of focal cartilage and osteochondral defects on the